VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase iii, Randomized, Double-Blind, Placebo-Controlled Trial

Category Primary study
JournalEUROPEAN JOURNAL OF CANCER
Year 2011
This article has no abstract
Epistemonikos ID: 0b1d9af715be7899793e3aab0bdb4f7613365e11
First added on: Feb 04, 2025